227 related articles for article (PubMed ID: 12173118)
1. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Goldstein EJ; Snydman DR
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
5. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
7. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children.
Lin WJ; Lo WT; Chu CC; Chu ML; Wang CC
J Microbiol Immunol Infect; 2006 Jun; 39(3):249-54. PubMed ID: 16783457
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
9. Role of newer antimicrobial agents in the treatment of mixed aerobic and anaerobic infections.
Karam GH; Sanders CV; Aldridge KE
Surg Gynecol Obstet; 1991; 172 Suppl():57-64. PubMed ID: 2024228
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of newer quinolones against bacteroides group organisms.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein E; Finegold S; Harrell L; Hecht DW; Jenkins S; Pierson C; Venezia R; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2002 Oct; 46(10):3276-9. PubMed ID: 12234859
[TBL] [Abstract][Full Text] [Related]
11. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections.
Claros M; Citron DM; Goldstein EJ; Merriam CV; Tyrrell KL
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):546-8. PubMed ID: 23727512
[TBL] [Abstract][Full Text] [Related]
12. Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
Goldstein EJ; Citron DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):447-54. PubMed ID: 19249176
[TBL] [Abstract][Full Text] [Related]
13. Bacteroides fragilis: a case study of bacteremia and septic arthritis.
Martin T; Aziz H
Clin Lab Sci; 2009; 22(3):131-5. PubMed ID: 19827405
[TBL] [Abstract][Full Text] [Related]
14. Treatment of anaerobic infections: an overview.
Finegold SM
Scand J Infect Dis Suppl; 1985; 46():89-95. PubMed ID: 3865355
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
16. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
17. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
18. Carbapenem resistance in Bacteroides fragilis: A review of molecular mechanisms.
Yekani M; Rezaee MA; Beheshtirouy S; Baghi HB; Bazmani A; Farzinazar A; Memar MY; Sóki J
Anaerobe; 2022 Aug; 76():102606. PubMed ID: 35738484
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
20. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]